IBB icon

iShares Biotechnology ETF
IBB

Overview Fund Activity

824 hedge funds and large institutions have $4.56B invested in iShares Biotechnology ETF in 2022 Q3 according to their latest regulatory filings, with 56 funds opening new positions, 228 increasing their positions, 300 reducing their positions, and 73 closing their positions.

Holders
824
Holders Change
-29
Holders Change %
-3.4%
% of All Funds
14.25%
Holding in Top 10
14
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-6.67%
% of All Funds
0.24%
New
56
Increased
228
Reduced
300
Closed
73
Calls
$257M
Puts
$721M
Net Calls
-$464M
Net Calls Change
-$386M

Top Buyers

1
Morgan Stanley
1
Morgan Stanley
New York
$434M
2
GI
2
Gradient Investments
Minnesota
$32.1M
3
Barclays
3
Barclays
United Kingdom
$45.8M
4
IUHSA
4
Itau Unibanco Holding S.A.
Brazil
$28.5M
5
CB
5
Commerce Bank
Missouri
$80.6M

Top Sellers

1
MPCL
1
My Personal CFO LLC
Washington
$787K
2
Bank of America
2
Bank of America
North Carolina
$1.18B
3
Citigroup
3
Citigroup
New York
$183M
4
UBS Group
4
UBS Group
Switzerland
$180M
5
E
5
Ergoteles
New York
$1.48M
Name Market Value Shares Shares
Change 		Shares
Change %
SM
901
SG3 Management
Puerto Rico
– – – –
DTIM
902
Danda Trouve Investment Management
Kansas
$0 1 – –
CAM
903
CenterStar Asset Management
Illinois
– – – –
EIM
904
Elliott Investment Management
Florida
– – – –
FMP
905
Financial Management Professionals
Texas
$0 3 – –
PCM
906
Pentwater Capital Management
Florida
– – – –
SA
907
SpiderRock Advisors
Delaware
– – – –
FCM
908
Farallon Capital Management
California
– – – –
CA
909
Continental Advisors
Utah
– – – –
HT
910
HAP Trading
New York
– – – –
AWM
911
Aspire Wealth Management
Massachusetts
$0 4 – –
33 34 35 36
37